Abbott admits guilt in Depakote off-label case; paying $1.6bn
This article was originally published in Scrip
Executive Summary
US drug maker Abbott pleaded guilty to misbranding its antiseizure and biopolar medicine Depakote (divalproex) by promoting it as a therapy to control agitation and aggression in elderly dementia patients and as a treatment for schizophrenia – indications not approved by the US FDA, prosecutors said on 7 May.